Treatment for hemophilia now a days is very effective. The missing clotting factor is injected into the bloodstream with a needle. Bleeding stops when extra clotting factor pass the spot that is bleeding. Bleeding should be diagnosed as fast as possible. Faster treatment helps in less pain and damage to the joints, muscles and organs. If bleeding is treated fast, lesser blood substitutes are required to stop the bleeding. With multiple treatment options for haemophilia cure now being available, products and proper care, people with hemophilia can live healthy lives. Mortality increases at younger age due to unavailability and accessibility of treatment options.
Factor concentrates are the treatment of selection for hemophilia. They can be made from human blood (known as plasma-derived products) or manufactured basically genetically engineered cells that carry a human factor gene (known as recombinant products). Factor concentrates are made in sophisticated manufacturing facilities. All commercially prepared factor concentrates are treated to edit or inactivate blood-borne viruses.
Cryoprecipitate is derived from blood and contains a moderately high level focus of clotting factor VIII (but not IX). It is effective for joint and muscle bleeds, but is less safe from viral contamination than concentrates and is harder to store and administer. Cryoprecipitate can be made at local blood collection facilities.
In fresh frozen plasma (FFP) the red cells have been removed, leaving the blood proteins content clotting factors VIII and IX. It is less effective than cryoprecipitate for the treatment of hemophilia A because the factor VIII is less concentrated. Large volumes of plasma must be transfused, which can lead to a complication known circulatory overload.
People with mild hemophilia A may sometimes use desmopressin (also known DDAVP) to treat minor bleeding. DDAVP is a synthetic hormone that stimulates the release of factor VIII.